SQZ Biotechnologies Company SQZ · Stock Open SQZ Biotechnologies Company in new tab
SQZ Biotechnologies Company Analysis (SQZ)
Is SQZ Biotechnologies Company a good investment? SQZ Biotechnologies Company (SQZ) is currently trading at 0.4350 USD.
Investor FAQ
Does SQZ Biotechnologies Company pay a dividend?
No, it does not currently pay a dividend.
What asset class is SQZ Biotechnologies Company?
SQZ Biotechnologies Company is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| July 7, 2023 | 1:10 |
Community Discussion